公开(公告)号：US20240066086A1

公开(公告)日：2024-02-29

申请号：US18458248

申请日：2023-08-30

Applicant: Allergan Sales, LLC

Inventor： Tony Wang ,  Kuniko Kadoya ,  Prithwiraj Maitra ,  Rahul Mehta ,  Elizabeth Makino

IPC: A61K36/282 ,  A61K9/00 ,  A61K31/01 ,  A61K31/05 ,  A61K31/075 ,  A61K31/191 ,  A61K31/196 ,  A61K31/197 ,  A61K31/205 ,  A61K31/343 ,  A61K31/351 ,  A61K31/375 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/6615 ,  A61K31/728 ,  A61K31/765 ,  A61K36/03 ,  A61K36/42 ,  A61K36/48 ,  A61K36/73 ,  A61K36/87 ,  A61K36/886 ,  A61K38/07 ,  A61K45/06 ,  A61P17/00

CPC classification number: A61K36/282 ,  A61K9/0014 ,  A61K31/01 ,  A61K31/05 ,  A61K31/075 ,  A61K31/191 ,  A61K31/196 ,  A61K31/197 ,  A61K31/205 ,  A61K31/343 ,  A61K31/351 ,  A61K31/375 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/6615 ,  A61K31/728 ,  A61K31/765 ,  A61K36/03 ,  A61K36/42 ,  A61K36/48 ,  A61K36/73 ,  A61K36/87 ,  A61K36/886 ,  A61K38/07 ,  A61K45/06 ,  A61P17/00

Abstract: The present invention relates to topical compositions that can be used to treat melanin or pigmentation disorders and methods of using the compositions.

公开(公告)号：US11884624B2

公开(公告)日：2024-01-30

申请号：US17343038

申请日：2021-06-09

Applicant: Cayman Chemical Company, Inc.

Inventor： Stephen Douglas Barrett ,  Fred Lawrence Ciske ,  Joseph Michael Colombo ,  Gregory William Endres ,  Bradlee David Germain ,  Andriy Kornilov ,  James Bernard Kramer ,  Adam Uzieblo ,  Kirk M. Maxey

IPC: C07D207/273 ,  C07D207/26 ,  C07D409/06 ,  A61K31/4025 ,  A61K31/4015 ,  A61L24/00 ,  A61L24/02 ,  A61L27/12 ,  A61L27/36 ,  A61L27/54 ,  A61L27/58

CPC classification number: C07D207/273 ,  A61K31/4015 ,  A61K31/4025 ,  A61L24/0015 ,  A61L24/0042 ,  A61L24/02 ,  A61L27/12 ,  A61L27/365 ,  A61L27/3608 ,  A61L27/54 ,  A61L27/58 ,  C07D207/26 ,  C07D409/06 ,  A61L2300/412 ,  A61L2300/604 ,  A61L2430/02

Abstract: Disclosed herein are compounds of formula (I)




and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

公开(公告)号：US20240016800A1

公开(公告)日：2024-01-18

申请号：US18461562

申请日：2023-09-06

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： Thomas CHEN

IPC: A61K31/495 ,  C07D231/12 ,  A61K31/4188 ,  A61K47/54 ,  C07B59/00 ,  A61K31/4015 ,  A61K9/00 ,  A61K31/045 ,  A61K31/415 ,  C07D207/26 ,  C07C33/14 ,  C07D487/04 ,  A61K45/06 ,  A61N5/10 ,  A61K31/635 ,  A61K47/55 ,  A61K31/366

CPC classification number: A61K31/495 ,  C07D231/12 ,  A61K31/4188 ,  A61K47/543 ,  C07B59/00 ,  A61K31/4015 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/415 ,  C07D207/26 ,  C07C33/14 ,  A61K47/542 ,  A61K47/54 ,  C07D487/04 ,  A61K45/06 ,  A61N5/10 ,  A61K31/635 ,  A61K47/55 ,  A61K31/366 ,  C07C2601/16 ,  C07B2200/05

Abstract: The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

公开(公告)号：US11872369B1

公开(公告)日：2024-01-16

申请号：US17178799

申请日：2021-02-18

Applicant: Fresenius Kabi Deutschland GmbH

Inventor： David R. Schiff ,  Vladlena Belozerova ,  Jason Zerweck

IPC: A61M5/14 ,  A61M5/142 ,  A61K31/4015 ,  A61M5/158

CPC classification number: A61M5/14248 ,  A61K31/4015 ,  A61M2005/14252 ,  A61M2005/1583 ,  A61M2005/1585 ,  A61M2205/15 ,  A61M2205/3317 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/8206

Abstract: Described herein are wearable devices and methods for medicament delivery. Example devices can include a housing having an underside adapted to be proximate to a skin surface, and a reservoir disposed in the housing, the reservoir configured to be filled with a medicament to be delivered to the patient. The devices can include a cannula disposed within the housing and coupled to the reservoir, in which the cannula configured to protrude from a port defined by the housing to be positioned in the skin surface. The devices can further include a capacitive sensor configured to detect whether the medicament has leaked from the delivery device, in which the capacitive sensor includes a conductor disposed in a portion of the underside of the housing.

公开(公告)号：US11737997B2

公开(公告)日：2023-08-29

申请号：US16795779

申请日：2020-02-20

Applicant: Merck Patent GmbH

Inventor： Alexander Paul Schiller ,  Lisa Eckelhoefer ,  Julia Bleifuss ,  Andrew Philip Salazar ,  Joerg von Hagen

IPC: A61K31/198 ,  A61K33/06 ,  A61K31/4015 ,  A61P3/14

CPC classification number: A61K31/198 ,  A61K31/4015 ,  A61K33/06 ,  A61P3/14

Abstract: The present invention relates to mixtures of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate and methods including this mixture including specific mixtures of such components and a formulations consisting of the mixture and a solvent.

公开(公告)号：US20230251276A1

公开(公告)日：2023-08-10

申请号：US18102852

申请日：2023-01-30

Applicant: Cognizance Biomarkers LLC

Inventor： Todd WALLACH ,  Peter CRINO ,  John POLLARD ,  Elizabeth BRAND ,  Maura STRAUMAN ,  Christopher HOLLENBEAK ,  Richard ST. CLAIR ,  Jeffrey BOTBYL ,  John GLEDHILL

IPC: G01N33/68 ,  A61K31/27 ,  A61K31/4166 ,  A61K31/515 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/20 ,  A61K31/513 ,  A61K31/5513 ,  A61K31/53 ,  A61K31/551

CPC classification number: G01N33/6896 ,  A61K31/27 ,  A61K31/4166 ,  A61K31/515 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/20 ,  A61K31/513 ,  A61K31/5513 ,  A61K31/53 ,  A61K31/551 ,  G01N2800/2857

Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computer systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic methods, kits and predictive models provided herein provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.

公开(公告)号：US20230225979A1

公开(公告)日：2023-07-20

申请号：US17998524

申请日：2021-05-11

Applicant: MOGON PHARMACEUTICALS SAGL

Inventor： Massimo Pedrani

IPC: A61K9/28 ,  A61K9/20 ,  A61K9/00 ,  A61K31/737 ,  A61K38/40 ,  A61K31/09 ,  A61K31/353 ,  A61K31/05 ,  A61K31/385 ,  A61K31/7076 ,  A61K31/7008 ,  A61K36/82 ,  A61K31/122 ,  A61K31/197 ,  A61K31/4015 ,  A61K31/198 ,  A61K31/145

CPC classification number: A61K9/2866 ,  A61K9/2054 ,  A61K9/0053 ,  A61K9/2027 ,  A61K31/737 ,  A61K38/40 ,  A61K31/09 ,  A61K31/353 ,  A61K31/05 ,  A61K31/385 ,  A61K31/7076 ,  A61K31/7008 ,  A61K36/82 ,  A61K31/122 ,  A61K31/197 ,  A61K31/4015 ,  A61K31/198 ,  A61K31/145

Abstract: The present invention relates to solid oral compositions with controlled release of active ingredients, comprising a core consisting of a monolithic matrix comprising at least one low-, medium- or high-viscosity hydroxypropyl methylcellulose, or a mixture thereof, a hydroxypropyl cellulose (HPC) and one or more superdisintegrant polymers, and an outer coating of said core consisting of a layer comprising hydroxypropyl methylcellulose and/or ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.

公开(公告)号：US11690821B2

公开(公告)日：2023-07-04

申请号：US17080471

申请日：2020-10-26

Applicant: ANAVEX LIFE SCIENCES CORP.

Inventor： Christopher U. Missling ,  Cameron Durrant

IPC: A61K31/341 ,  A61K31/4015 ,  A61K31/445 ,  A61K31/55 ,  A61P25/08 ,  C07D307/14 ,  A61K31/27 ,  A61K31/165 ,  A61K45/06

CPC classification number: A61K31/341 ,  A61K31/165 ,  A61K31/27 ,  A61K31/4015 ,  A61K31/445 ,  A61K31/55 ,  A61K45/06 ,  A61P25/08 ,  C07D307/14 ,  A61K31/341 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/445 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00

Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.

公开(公告)号：US20230181534A1

公开(公告)日：2023-06-15

申请号：US18076256

申请日：2022-12-06

Applicant: Celgene International II Sàrl

Inventor： Mohit TRIKHA ,  Nancy LEVIN ,  Benjamin WINOGRAD

IPC: A61K31/407 ,  A61N1/36 ,  A61P25/00 ,  A61P35/00 ,  A61K31/4015 ,  A61N5/10 ,  C07K16/22

CPC classification number: A61K31/407 ,  A61K31/4015 ,  A61N1/36002 ,  A61N5/10 ,  A61P25/00 ,  A61P35/00 ,  C07K16/22 ,  A61K45/06

Abstract: The present disclosure is related to dosage strategies for the treatment of CNS cancers with proteasome inhibitors (e.g., marizomib). For instance, the disclosure is related to strategies in which a proteasome inhibitor (e.g., marizomib) is administered at the same or higher dosage even after a subject has experienced a CNS-related adverse event.

公开(公告)号：US11622956B1

公开(公告)日：2023-04-11

申请号：US16913834

申请日：2020-06-26

Applicant: RCR BIOPHARMA

Inventor： Irena Raskin

IPC: A61K31/352 ,  A61K31/05 ,  A61K31/515 ,  A61K31/4015 ,  A61K31/423 ,  A61K31/195 ,  A61K33/00 ,  A61K9/00

Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.